COMMUNIQUÉS West-GlobeNewswire

Valneva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son rapport annuel américain « Form 20-F »
25/03/2024
Saint-Herblain (France), 25 mars 2024 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui le dépôt, le 22 mars 2024, de son Document d’enregistrement universel [...]
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
25/03/2024
Oslo, March 25, 2024, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") at 14:00 CET on April 18, 2024. The General Meeting will be held electronically. For [...]
Congress Passes Bills Making Major Investments in Alzheimer’s
23/03/2024
Bill Increases Funding for Alzheimer’s Research and Prevention Efforts WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22/03/2024
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22/03/2024
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and [...]
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
22/03/2024
Leading Contract Research Organization to carry out pharmacological studies, part of planned FDA Investigational New Drug (IND) application TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic [...]
Vistin Pharma ASA: Mandatory notification of trade
22/03/2024
Pactum Vekst AS has on March 22, 2024 sold 527 960 shares in Vistin Pharma ASA at a price of NOK 22,10 per share. Espen W. Marcussen, Chair of the board in Pactum Vekst AS, is a primary insider and board member of [...]
Nutra Pharma Corp. Reaches Settlement with SEC
22/03/2024
Nutra Pharma Corp. has reached a bifurcated settlement with the SEC along with its CEO and a Consultant to the company CORAL SPRINGS, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC: NPHC), (“ [...]
IBEX Reports Results for the Second Quarter and Six Months Ended January 31, 2024
22/03/2024
MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2024. “We [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/03/2024
CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Alvotech Announces Increase in Number of Own Shares
22/03/2024
Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of [...]
Alvotech Announces Increase in Number of Own Shares
22/03/2024
REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22/03/2024
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant Expense-reduction Measures [...]
Veru Reschedules Annual Meeting of Shareholders
22/03/2024
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22, 2024 (GLOBE NEWSWIRE [...]
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
22/03/2024
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule [...]
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023
22/03/2024
Daix (France), Long Island City (New York, Etats-Unis) , le 22 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/03/2024
NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
22/03/2024
Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development work Today’s update on [...]
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22/03/2024
FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and [...]

Pages